Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the treatment of systemic sclerosis. Read more >>

Share this post